PUBLIC HEALTH SERVICE

COMMERCIAL EVALUATION - BIOLOGICAL MATERIALS LICENSE AGREEMENT

This Agreement is based on the model Commercial Evaluation - Biological Material License Agreement adopted by the U.S. Public Health Service ("PHS") Technology Transfer Policy Board for use by components of the National Institutes of Health ("NIH"), the Centers for Disease Control and Prevention ("CDC"), and the Food and Drug Administration ("FDA"), which are agencies of the PHS within the Department of Health and Human Services ("HHS").

This Cover Page identifies the Parties to this Agreement:

The U.S. Department of Health and Human Services, as represented by

[Insert the full name of the IC]

an Institute or Center (hereinafter referred to as the "IC") of the

[INSERT as appropriate: NIH, CDC, or FDA]

and

[Insert Company’s official name],

hereinafter referred to as the "Licensee",

having offices at [Insert Company’s address],

created and operating under the laws of [Insert State of Incorporation].

Tax ID No.:_________________
1. Definitions:

(a) “Benchmark Royalty” means a royalty due upon the six (6) month anniversary of the Effective Date. The Benchmark Royalty will be payable upon the six (6) month anniversary of the Effective Date unless Licensee provides notice of termination of this Agreement at least thirty (30) days prior to the due date of the Benchmark Royalty.

(b) “Effective Date” means the date when the last party to sign has executed this Agreement.

(c) “FDA” means the Food and Drug Administration.

(d) “Government” means the government of the United States of America.

(e) “Licensed Field of Use” means the use of Licensed Products for internal research purposes only. The Licensed Field of Use specifically excludes the sale or other distribution of the Materials or the Licensed Products for any purpose, including the use of the Materials or the Licensed Products in a fee-for-service assay.

(f) “Licensed Products” means the _______________ produced by the Materials and compositions incorporating the _______________ produced by the Materials.

(g) “Materials” means the following biological materials, including all progeny, subclones, or unmodified derivatives thereof:
   _______________, as described in
   __________ and developed in the laboratory of
   ____________________________.

(h) “Materials Royalty” means a royalty due upon the six (6) month anniversary of the Effective Date when additional Materials are required.

2. Licensee desires to obtain:

(a) a license from IC to use the Materials provided under this Agreement to evaluate the Licensed Products for a period of up to six (6) months from the Effective Date; and

(b) a license from IC to use the Materials or the Licensed Products in its commercial research or product development and marketing activities upon the payment of the Benchmark Royalty.

3. Licensee intends:

(a) to conduct laboratory experiments under this Agreement to evaluate the suitability of the Licensed Products in the Licensed Field of Use; and
(b) to continue to use the Materials or the Licensed Products in the Licensed Field of Use only upon payment of the Benchmark Royalty.

4. Licensee represents that it has the facilities, personnel, and expertise to use the Materials and the Licensed Products, and agrees to expend reasonable efforts and resources on research and development of the Licensed Products unless this Agreement is otherwise terminated or expired.

5. IC hereby grants to Licensee a non-exclusive license, within its research facilities, to make, have made and use, but not to sell, the Materials or the Licensed Products within the Licensed Field of Use. Licensee agrees that the continued use of the Materials or the Licensed Products after the six (6) month anniversary of the Effective Date will occur only pursuant to the payment of the Benchmark Royalty. The continued use of the Materials or the Licensed Products after the six (6) month anniversary of the Effective Date without payment of the Benchmark Royalty will be considered a material breach of this Agreement.

6. Licensee hereby agrees to pay IC:

(a) A non-creditable, non-refundable license issue royalty of ________ dollars ($X) no later than sixty (60) days following the Effective Date.

(b) A non-creditable, non-refundable Benchmark Royalty of ________ dollars ($X) no later than six (6) months after the Effective Date. This Benchmark Royalty is due unless Licensee indicates to IC that it will terminate the Agreement in writing and at least thirty (30) days prior to the due date of the Benchmark Royalty.

(c) (only if additional Materials are required) A non-creditable, non-refundable Materials Royalty of ________ dollars ($X) if additional Materials are required at the six (6) month anniversary of the Effective Date. The Materials Royalty is due only if IC has been requested to send the additional Materials.

(d) A non-refundable annual royalty of ________ dollars ($X), as follows:

i) The first annual royalty is due and payable no later than the six (6) month anniversary of the Effective Date and may be prorated according to the fraction of the calendar year remaining between the six (6) month anniversary of the Effective Date and the next subsequent January 1.

ii) Each subsequent annual royalty shall be due and payable on January 1 of each calendar year.

iii) Each annual royalty is due unless Licensee indicates to IC that it will terminate the Agreement in writing and at least thirty (30) days prior to its due date.

All payments required under this Agreement shall be paid in U.S. dollars and payment options are listed in Appendix B. For conversion of foreign currency to U.S. dollars, the conversion rate shall be the New York foreign exchange rate quoted in The Wall Street Journal on the day that the payment is due.
iv) Any loss of exchange, value, taxes, or other expenses incurred in the transfer or conversion to U.S. dollars shall be paid entirely by Licensee; and

v) Additional royalties may be assessed by IC on any payment that is more than ninety (90) days overdue at the rate of one percent (1%) per month. This one percent (1%) per month rate may be applied retroactively from the original due date until the date of receipt by IC of the overdue payment and additional royalties. The payment of any additional royalties shall not prevent IC from exercising any other rights it may have as a consequence of the lateness of any payment.

7. IC agrees, upon receipt and verification of the license issue royalty, as required by Paragraph 6(a), to provide Licensee with XXX (please enter quantity) of the Materials, as available, and to replace the Materials, as available and at reasonable cost, in the event of their unintentional destruction. [If additional Materials are required upon the six (6) month anniversary of the Effective Date, IC agrees, after receipt and verification of the Materials Royalty, as required by Paragraph 6(c), to provide Licensee with an additional XXX (please enter quantity) of the Materials, as available, and to replace the Materials, as available and at reasonable cost, in the event of their unintentional destruction (only if necessary)]. IC shall provide the Materials to Licensee at Licensee’s expense and as specified in Appendix A.

8. This Agreement shall become effective on the Effective Date unless the provisions of Paragraph 26 are not fulfilled, and shall expire exactly ____ (X) years after the Effective Date.

9. Within thirty (30) days of the termination or expiration of this Agreement, Licensee shall return all Materials and Licensed Products to IC or provide IC with written certification of their destruction.

10. Licensee agrees to retain control over the Materials and the Licensed Products, and not to distribute them to third parties without the prior written consent of IC.

11. This Agreement does not preclude IC or the FDA from distributing the Materials or the Licensed Products to third parties for research or commercial purposes. Licensee acknowledges that third parties also may be evaluating the Licensed Products or the Materials for a variety of commercial purposes.

12. By this Agreement, IC grants no patent rights expressly or by implication to any anticipated or pending IC or FDA patent applications or issued patents.

13. NO WARRANTIES, EXPRESS OR IMPLIED, ARE OFFERED AS TO THE MERCHANTABILITY OR FITNESS FOR ANY PURPOSE OF THE MATERIALS OR THE LICENSED PRODUCTS PROVIDED TO LICENSEE UNDER THIS AGREEMENT, OR THAT THE MATERIALS OR LICENSED PRODUCTS MAY BE EXPLOITED WITHOUT INFRINGING THE PATENT RIGHTS OF ANY THIRD PARTIES. Licensee accepts license rights to the Licensed Products and the Materials “as is” and IC does not offer any guarantee of any kind.

14. Licensee agrees to indemnify and hold harmless IC and the Government from any claims, costs, damages, or losses that may arise from or through Licensee’s use of the Materials or the Licensed Products. Licensee further agrees that it shall not by its action bring the Government into any lawsuit involving the Materials or the Licensed Products.
15. **Licensee** agrees in its use of the **Materials** or the **Licensed Products** to comply with all applicable statutes, regulations, and guidelines, including NIH and HHS regulations and guidelines. **Licensee** agrees not to use the **Materials** or the **Licensed Products** for research involving human subjects or clinical trials in the United States without complying with 21 C.F.R. Part 50 and 45 C.F.R. Part 46. **Licensee** agrees not to use the **Materials** or the **Licensed Products** for research involving human subjects or clinical trials outside of the United States without notifying IC, in writing, of such research or trials and complying with the applicable regulations of the appropriate national control authorities. Written notification to IC of research involving human subjects or clinical trials outside of the United States shall be given no later than sixty (60) days prior to commencement of such research or trials.

16. The **Licensee** may terminate this **Agreement** upon thirty (30) days written notice to the IC, but only after sixty (60) days from the **Effective Date**.

17. The IC may terminate this **Agreement** if the **Licensee** is in default in the performance of any material obligation under this **Agreement**, and if the default has not been remedied within ninety (90) days after the date of written notice by the IC of the default.

18. Within ninety (90) days of termination, expiration or term extension of this **Agreement**, the **Licensee** agrees to submit a report to the IC, and to submit to the IC payment of any royalties due.

   (a) The report shall include, but not be limited to, progress on the research and development involving the **Materials** or the **Licensed Products** and use of the **Materials** or the **Licensed Products**. The **Licensee** shall send the report to the IC at the Mailing Address for **Agreement** notices indicated on the Signature Page or electronically mailed to the email address indicated on the Signature Page;

   (b) If the term of the **Agreement** is extended at the **Licensee**’s request, then the IC and the **Licensee** will negotiate in good faith regarding the schedule for reports regarding the information required in 18(a);

   (c) If the term of this **Agreement** is longer than ten (10) years, then the IC may request a status update report after the fifth (5th) year of the **Agreement**; and

   (d) The **Licensee** may not be granted additional IC licenses if this reporting requirement is not fulfilled.

19. All plans and reports required by this **Agreement** shall be treated by the IC as commercial and financial information obtained from a person and as privileged and confidential and, to the extent permitted by law, not subject to disclosure under the Freedom of Information Act, 5 U.S.C. 552.

20. The **Licensee** is encouraged to publish the results of its research projects using the **Materials** or the **Licensed Products**. In all oral presentations or written publications concerning the **Materials** or the **Licensed Products**, the **Licensee** shall acknowledge the contribution of Dr. __________ and the HHS agency supplying the **Materials**, unless requested otherwise by the IC or the FDA or Dr. __________.

21. **Licensee** agrees to supply the laboratory of Dr. __________ at IC, at no charge, reasonable quantities of **Materials** or the **Licensed Products** that **Licensee** makes or uses, provided that either IC or Dr. __________ makes a request for said **Materials** or **Licensed Products**.
22. This Agreement shall be construed in accordance with U.S. Federal law, as interpreted and applied by the U.S. Federal courts in the District of Columbia. Federal law and regulations shall preempt any conflicting or inconsistent provisions in this Agreement. Licensee agrees to be subject to the jurisdiction of U.S. courts.

23. This Agreement constitutes the entire understanding of IC and Licensee and supersedes all prior agreements and understandings with respect to the Materials and the Licensed Products.

24. The provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable under any controlling body of law, the invalidity or unenforceability of any provision of this Agreement, shall not in any way affect the validity or enforceability of the remaining provisions of this Agreement.

25. Paragraphs 6, 9, 13, 14, 18, 19, 20 and 25 of this Agreement shall survive termination or expiration of this Agreement.

26. The terms and conditions of this Agreement shall, at IC’s sole option, be considered by IC to be withdrawn from Licensee’s consideration and the terms and conditions of this Agreement, and the Agreement itself to be null and void, unless this Agreement is executed by the Licensee and a fully executed original is received by IC within sixty (60) days from the date of IC signature found at the Signature Page.

SIGNATURES BEGIN ON NEXT PAGE
NIH COMMERCIAL EVALUATION AND BIOLOGICAL MATERIALS-INTERNAL USE LICENSE AGREEMENT

SIGNATURE PAGE

In Witness Whereof, the parties have executed this Agreement on the dates set forth below. Any communication or notice to be given shall be forwarded to the respective addresses listed below.

For IC:

______________________________
Name

______________________________
Title

National Institutes of Health

Address for Agreement notices and reports:

E-mail: LicenseNotices_Reports@mail.nih.gov (preferred)

Mail: License Compliance and Administration
      Monitoring & Enforcement
      Office of Technology Transfer
      National Institutes of Health
      6701 Rockledge Drive, Suite 700, MS 7788
      Bethesda, Maryland 20892 U.S.A.

      (For courier deliveries please check https://www.ott.nih.gov/licensing/license-noticesreports)
For **Licensee** (Upon, information and belief, the undersigned expressly certifies or affirms that the contents of any statements of **Licensee** made or referred to in this document are truthful and accurate.):

by:

______________________________
Signature of Authorized Official

______________________________
Date

______________________________
Printed Name

______________________________
Title

I. Official and Mailing Address for **Agreement** notices:

______________________________
Name

______________________________
Title

______________________________
Mailing Address

Email Address: ________________________________

Phone: ________________________________

Fax: ________________________________

II. Official and Mailing Address for Financial notices (The **Licensee**’s contact person for royalty payments)

______________________________
Name

______________________________
Title

______________________________
Mailing Address
Any false or misleading statements made, presented, or submitted to the Government, including any relevant omissions, under this Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C. §§3801-3812 (civil liability) and 18 U.S.C. §1001 (criminal liability including fine(s) and/or imprisonment).
APPENDIX A – SHIPPING INFORMATION

The Licensee’s Shipping Contact: information or questions regarding shipping should be directed to the Licensee’s Shipping Contact at:

<table>
<thead>
<tr>
<th>Shipping Contact’s Name</th>
<th>Title</th>
</tr>
</thead>
</table>

Phone: () __________________ Fax: () ___________ E-mail: __________________

Shipping Address: Name & Address to which Materials should be shipped (please be specific):

Company Name & Department

Address:

The Licensee's shipping carrier and account number to be used for shipping purposes:

__________________________________________________________________
APPENDIX B — ROYALTY PAYMENT OPTIONS
New Payment Options Effective March 2018

The License Number MUST appear on payments, reports and correspondence.

Credit and Debit Card Payments: Credit and debit card payments can be submitted for amounts up to $24,999. Submit your payment through the U.S. Treasury website located at: https://www.pay.gov/public/form/start/28680443.

Automated Clearing House (ACH) for payments through U.S. banks only

The IC encourages its licensees to submit electronic funds transfer payments through the Automated Clearing House (ACH). Submit your ACH payment through the U.S. Treasury website located at: https://www.pay.gov/public/form/start/28680443. Please note that the IC "only" accepts ACH payments through this U.S. Treasury website.

Electronic Funds Wire Transfers: The following account information is provided for wire payments. In order to process payment via Electronic Funds Wire Transfer sender MUST supply the following information within the transmission:

Drawn on a U.S. bank account via FEDWIRE:

Please provide the following instructions to your Financial Institution for the remittance of Fedwire payments to the NIH ROYALTY FUND.

<table>
<thead>
<tr>
<th>Fedwire Field Tag</th>
<th>Fedwire Field Name</th>
<th>Required Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>{1510}</td>
<td>Type/Subtype</td>
<td>1000</td>
</tr>
<tr>
<td></td>
<td>Amount</td>
<td>(enter payment amount)</td>
</tr>
<tr>
<td>{2000}</td>
<td>Receiver ABA routing number*</td>
<td>02103004</td>
</tr>
<tr>
<td>{3400}</td>
<td>Receiver ABA short name</td>
<td>TREAS NYC</td>
</tr>
<tr>
<td>{3600}</td>
<td>Business Function Code</td>
<td>CTR (or CTP)</td>
</tr>
<tr>
<td>{4200}</td>
<td>Beneficiary Identifier (account number)</td>
<td>(enter 12 digit gateway account #) 875080031006</td>
</tr>
<tr>
<td>{4200}</td>
<td>Beneficiary Name</td>
<td>(enter agency name associated with the Beneficiary Identifier) DHHS / NIH (75080031)</td>
</tr>
<tr>
<td>{5000}</td>
<td>Originator</td>
<td>(enter the name of the originator of the payment) COMPANY NAME</td>
</tr>
<tr>
<td>{6000}</td>
<td>Originator to Beneficiary Information – Line 1</td>
<td>(enter information to identify the purpose of the payment) ROYALTY</td>
</tr>
<tr>
<td>{6000}</td>
<td>Originator to Beneficiary Information – Line 2</td>
<td>(enter information to identify the purpose of the payment) LICENSE NUMBER</td>
</tr>
<tr>
<td>{6000}</td>
<td>Originator to Beneficiary Information – Line 3</td>
<td>(enter information to identify the purpose of the payment) INVOICE NUMBER</td>
</tr>
<tr>
<td>{6000}</td>
<td>Originator to Beneficiary Information – Line 4</td>
<td>(enter information to identify the purpose of the payment)</td>
</tr>
</tbody>
</table>
**Fedwire Field Tag** | **Fedwire Field Name** | **Required Information**
--- | --- | ---
{1510} | Type/Subtype | 1000
{2000} | Amount | (enter payment amount)
{3100} | Sender Bank ABA routing number | (enter the US correspondent bank’s ABA routing number)
{3400} | Receiver ABA routing number* | 021030004
{3400} | Receiver ABA short name | TREAS NYC
{3600} | Business Function Code | CTR (or CTP)
{4200} | Beneficiary Identifier (account number)** | (enter 12 digit gateway account #) 875080031006
{4200} | Beneficiary Name | (enter agency name associated with the Beneficiary Identifier)
DHHS / NIH (75080031)
{5000} | Originator | (enter the name of the originator of the payment)
COMPANY’S NAME
{6000} | Originator to Beneficiary Information – Line 1 | (enter information to identify the purpose of the payment)
ROYALTY
{6000} | Originator to Beneficiary Information – Line 2 | (enter information to identify the purpose of the payment)
LICENSE NUMBER
{6000} | Originator to Beneficiary Information – Line 3 | (enter information to identify the purpose of the payment)
INVOICE NUMBER
{6000} | Originator to Beneficiary Information – Line 4 | (enter information to identify the purpose of the payment)

**Notes:**
*The financial institution address for Treasury’s routing number is 33 Liberty Street, New York, NY 10045.
**Anything other than the 12 digit gateway account # will cause the Fedwire to be returned – SWIFT CODE: FRNYUS33

**Agency Contacts:** Office of Technology Transfer (OTT) (301) 496-7057 OTT-Royalties@mail.nih.gov

Drawn on a foreign bank account via FEDWIRE:

The following instructions pertain to the Fedwire Network. Deposits made in US Dollars (USD).

Should your remitter utilize a correspondent US domestic bank in transferring electronic funds, the following Fedwire instructions are applicable.
Agency Contacts:
Office of Technology Transfer (OTT)  (301) 496-7057  OTT-Royalties@mail.nih.gov

Checks

All checks should be made payable to “NIH Patent Licensing”

Checks drawn on a **U.S. bank account** and sent by US Postal Service should be sent directly to the following address:

National Institutes of Health
P.O. Box 979071
St. Louis, MO 63197-9000

Checks drawn on a U.S. bank account and sent by **overnight or courier** should be sent to the following address:

US Bank
Government Lockbox SL-MO-C2GL
1005 Convention Plaza
St. Louis, MO 63101
Phone: 314-418-4087

Checks drawn on a **foreign bank account** should be sent directly to the following address:

National Institutes of Health
Office of Technology Transfer
License Compliance and Administration
Royalty Administration
6701 Rockledge Drive
Suite 700, MSC 7788
Bethesda, Maryland 20892